Board of Directors

Corey Goodman, Ph.D.

Executive Chairman

Dr. Goodman is a Managing Partner at venBio Partners. He is a scientist, entrepreneur, educator, and corporate executive. He was formerly President of Pfizer’s Biotherapeutics and Bioinnovation Center, and a member of Pfizer’s Executive Leadership Team, where he oversaw the discovery and development of biotherapeutics as well as innovative new technologies. Dr. Goodman co-founded Exelixis, Renovis, Second Genome, and Ossianix prior to joining venBio. He was CEO of Renovis as a private and public company, until its acquisition by Evotec A.G. As a result of the acquisition, Dr. Goodman served on the Evotec (XETRA: EVT) Supervisory Board from 2008 until 2009. He is former professor at Stanford University and University of California Berkeley, co-founder of Berkeley’s Wills Neuroscience Institute, Investigator with the Howard Hughes Medical Institute, and currently is Adjunct Professor at UC San Francisco and UC Berkeley. Dr. Goodman is an elected member of the U.S. National Academy of Sciences, the American Academy of Arts and Sciences, and the American Philosophical Society. His honors include, amongst others, the Alan T. Waterman Award, Canada Gairdner Biomedical Award, March of Dimes Prize in Developmental Biology, Reeve-Irvine Research Medal, and Dawson Prize in Genetics. Dr. Goodman is Council Chair of the California Council on Science and Technology. In addition, Dr. Goodman is currently Chair of the Board of ALX Oncology, Solstice Biologics, Heart Metabolics, Second Genome, and Adheren. He is a member of the board of Checkmate Pharmaceuticals. Dr. Goodman founded Labrys Biologics and was Chair of the Board up until its acquisition by Teva Pharmaceuticals.

Robert Adelman, M.D.

Dr. Adelman is a Managing Partner at venBio Partners. Dr. Adelman has a 30-year history of founding, investing in, and managing companies in the life sciences sector. Dr. Adelman received his undergraduate degree from University of California at Berkeley, his medical degree from Yale University, performed his residency at Cornell University Medical Center, and practiced surgery in New York and New Jersey. Before founding venBio, Dr. Adelman had a seven-year tenure as a Private Equity Partner at OrbiMed Advisors. There he was part of a team that invested $1.1B in both private and public companies across three venture capital funds. Dr. Adelman has co-founded a number of biotechnology companies. Dr. Adelman led venBio’s investment into Aragon Pharmaceuticals where he was a member of the Board of Directors until the company’s acquisition by Johnson & Johnson. He also led venBio’s investment into Seragon Pharmaceuticals where he was a member of the Board of Directors until the company’s acquisition by Genentech/Roche. Dr. Adelman is a member of the Board of Directors of Solstice Biologics, Heart Metabolics, Metacrine, and Precision Biosciences.

Caroline Gaynor

Caroline is Vice President at Lightstone Ventures (LSV), where she evaluates new investment opportunities in the biopharmaceutical and medical device sectors out of the firm’s Dublin office. Prior to joining Lightstone, Caroline held the position of commercial and clinical lead on a number of early stage medical device projects and is director and founder of a start up in the healthcare IT space. Caroline has more than 10 years’ experience in the pharmaceutical industry where she held a variety of operational roles in regulatory affairs, product management, marketing and strategic business development in the oncology space. More recently Caroline held a senior management position as head of market access & reimbursement for Bayer Ltd. Ireland where she was responsible for health technology assessment applications and reimbursement negotiations with the national health services for novel drugs in the cardiovascular, oncological and hormonal therapy space.

Jaume Pons, Ph.D.

Dr. Pons is President, Chief Executive Officer and co-founder of ALX Oncology. Dr. Pons previously served as Chief Scientific Officer and site head of Rinat (Pfizer), where he was responsible for portfolio delivery from idea to clinical development. He implemented the vision of a company unit following biology across therapeutic areas while generating advanced antibody technologies and turned Rinat into the center of cancer immunology for Pfizer. Dr. Pons is an inventor of fremanezumab, which was approved by the FDA in 2018, as well as two other antibodies in late-stage clinical development and has advanced nine additional antibodies into human trials in multiple therapeutic areas. As Senior Vice President of R&D, he was a member of Pfizer’s World R&D Leadership Team. Before Pfizer, Dr. Pons created and led Rinat’s protein engineering group and was a scientist at Chiron. Dr. Pons earned his Ph.D. in molecular and cell biology at the Institute on Fundamental Biology, Barcelona, and an M.S. in biotechnology and B.S. in biochemistry from Autonoma University of Barcelona. He conducted his postdoctoral studies in antibody engineering at the University of California, Berkeley.